Rich. we with call, Thanks key to XXXX. the was very today's and highlight technology candidates On candidates Protagonist, points we solid inflection ahead and for important as joining of anticipate for the milestones status year progression adequate development all with XXXX eventful of highly past peptide of we for begin now XXXX. you and of today. platform. from like the execution development thank We these would financial The resources diverse proprietary forward three six to a our end us support through I to drug review year year to move as from of afternoon three candidates, generated clinical look Good everyone our
our Rich the available may David will VP and Liu, be Executive all They session. and me Shames, of to Gupta, Suneel our Q&A R&D; you have address CSO Joining Chief during Operations Clinical Pharmacology. Medical today and Officer; our of Head is questions
to for Advisor review Kalkofen, and Following will financial our results, we my Finance Senior then our call will and overview, Don questions. the Accounting, up open
begin, focused on peptide to I that So Protagonist would emphasize to like therapeutics. is exclusively
and chemical Over years, platform new highly the past the entities distinctive have discover that plus peptide technology with us enables to attributes. optimized we engineering XX created
able therapeutics specific challenges that peptide designed with are large to addressed we approaches. be small Specifically, adequately develop address molecule medical to cannot classical antibody or
is of built pursue are do those know-how the that pipeline in projects the not have. platform, therapeutic accessing distinct now stages privileged or development. others opportunities unable that therefore candidates different barrier-to-entry towards in for and discovering the assets that are type a are medicine three of possess we as are our kind companies of to have the there we proprietary they able most Through we a and of We technology to developing undertake. other significant Thus, use platform of
an complex unmet Our hepcidin. like specific engineered of body. is most mimetic mimetic the as which our providing rare in drug is in blood the engineered of peptide to fall orphan structure, indications, Hepcidin in master comparison medical therefore, more agent. of of to for synthesize PTG-XXX more to potent, those iron opportunity the in many to for PTG-XXX, better properties therapeutic a diseases. less is synthetic a and is natural a It be the in development And hormone potential use for hepcidin. hormone, category drug to have advanced Thereby, regulator has indications. stable, multiple PTG-XXX address homeostasis peptide disorder-based asset the needs the natural easier
What for sets to potential here IBD. targeting drugs. been that already validated is from targeting In are oral have restricted injectable antibodies we gut-restricted, these bowel are developed pathways pathways. being that us approved biological aspects, validated other therapy oral are our approach IBD, those two orally or Our PN-XXX, inflammatory peptides as injectable apart PTG-XXX diseases antibody and these by marketed gut and stable
Our the receptor. Janssen's for comes Stelara validation IL-XX/XX Crohn's and approved clinical targets first injectable antibody IL-XX restricted asset this pathway that approach IBD is it The targets is oral PTG-XXX, therapeutic disease. and approved that for the from gut
is You synergize can partnership a around potential ready that random it patients, XXXX. X and study in Phase then of franchise. also to have half Crohn's that first extend initiated the the in and a as we by Janssen appreciate is the a offers be this to we PTG-XXX Janssen coincidence it Stelara not with PTG-XXX expect study for
space in Takeda's Our which PN-XXX biological injectable works. restricted alpha-X-beta-X IBD in Phase studies ENTYVIO, drug, antibody X integrin, volunteers. currently targets which PN-XXX, second is candidate same healthy asset target IBD in through gut the is oral the the
injectable therapy welcome companies modulators. oral available While inhibitors the antibodies is SXP and towards targeted are there IBD Stelara patients. options, and treatment that be injectable ENTYVIO in and witnessed multiple for already needle-free important as paradigm JAK work working IBD Oral option shift like validated in by oral options, like the and potential could proven treatment strong on a therapeutic antibodies by mechanisms safe potentially PTG-XXX through PN-XXX and and a a
clinical direct why barrier well-differentiated, have general, in to three unique, I unmet talked competition. how So, and are address until about assets and needs, a present now, our
can what us three talk in XXXX let the is beyond. what announcements the and of and and specifics assets about that status be is current expected milestones these Now,
end in through before, move be of mentioned these a are support financial to to with As strong position forward adequate fortunate programs to resources XXXX. of we the all
patients in characterized Medicines PTG-XXX no beta-thalassemia, production the drug and has Agency is rare many deficient we of vera, transfusion status study, serves is of five significantly fourth in Being or eight in Administration safety, XXX, syndrome, of from medication of patients. recently iron blood healthy a are received related XXX and as and half-life optimization U.S. has TRANSCEND well PTG-XXX PTG-XXX iron master chosen designation fast-track in blood and lifelong proof-of-concept mimetic clinical as of studies, this homeostasis, X Phase Drug blood the reductions a excessive patients XX open as in serum a to previously a polycythemia should U.S. in FDA. potential utility a and to as and clinical global It Currently, orphan the have as for arm, Food Phase with single such defective have Out in disorders, noted iron hereditary half-life We they review disease regulator to well levels body. Phase label by non-transfusion-dependent transfusions hours. of overload that requiring comparison often phase this, is PTG-XXX. be XX to readout to which the X achieving dose European hemochromatosis. cells was in dependent proof-of-concept, X as to With indication demonstrated mimetic study survive. pharmacodynamic there in longer in the dose let's have volunteers. the from a to of This on approved that have of shown First, evaluate hepcidin these a hepcidin, in designation beta-thalassemia, red we multiple pursue to XX both study hormone designed initiated natural beta-thalassemia study, is patients. transfusion-dependent expected patients myelodysplastic the hours dosing beta-thalassemia
and the patient satisfied of initial with the the report from study enrollment of results to half we in date, are TRANSCEND the year. expect to We rate second
Beyond PTG-XXX of potential second other the beta-thalassemia, and for a half indications strong to second we year. indication see the in initiate expect in
subcutaneous hepcidin on overview our that disorders mimetic the So was diseases. and for blood XXX
oral two us switch on IBD let Now, gears update our gut-restricted you and assets.
address IL-XX let's oral the antagonist, PTG-XXX. receptor First,
dose-limiting As entered no volunteers been XXXX as Phase ready drug well-tolerated to patients. preclinical when X it studies into U.S. preclinical of as the well by first it working teams toward and the be of Janssen adverse serious and IND Both Phase been Protagonist or completed the for Protagonist in studies study partnership a toxicities X objective half Since and with observed a together filing to patients events has then, Janssen found asset. healthy disease. begin mid-XXXX global evaluation a are refresher, with for in have around is with in we PTG-XXX the the Crohn's all in now was
strong strong IBD commitment a remains partner privileged experience like are with be gut-restricted and to and with oral deep-rooted patients. IBD we a such working as partnership with expertise option of towards Janssen a for and in therapeutic Our approach the field future
at Now, pharmacodynamics let's address on of volunteers, integrin in our is will also receptor wherein benefit or fully currently XXX tremendously we PK, and that blood measuring X effects establishing PN-XXX, RO. stage. we owned this currently occupancy study gut-restricted alpha-X-beta-X in from safety Phase are own or a our healthy besides PD oral developing antagonist,
And we patients. these data up between at an in-vivo of PN-XXX measures to-date. gut-restricted that earlier builds analog has integrin have Oral similar XXX October PN-XXX as Conference X good by UEGW the superiority are in-vitro established an had shown alpha-X-beta-X on correlation remission is a findings Phase colitis and PTG-XXX, the that antagonist, preclinical all clinical may investigated You with Talk pharmacodynamic presented of we XXXX. X in and studies a to ulcerative that recall rates and in wherein histological program oral an Phase
Diego. peptide overall Digestive for And PN-XXX preclinical We at the of with been XXX the create glad Sunday, Diseases have that switch Protagonist timelines. PN-XXX case, presentation accepted properties. the research describe for the oral of XXX us that engineering provides development a Conference conveniently of has backup XXXX platform, to notable from in versatility allows are in properties Week significantly to expanding findings to this improved candidates the without San the allowed share to an example which it May
of X of late the initial expecting Phase first ulcerative X in The XXXX. design volunteers with will U.S. half in results expected PD are colitis clinical healthy of with results XXX PK X of a safety IND study in XXXX. Phase Phase and study an the inform filing in from patients the XXX We
PTG-XXX, preliminary January. study accomplished year, year. in second besides of are from early eventful indication first, dosing specifics initiating the the second of year half hepcidin the XXXX the the another So, six first Two, three we beta-thalassemia three, already which in summary, With be beta-thalassemia TRANSCEND milestones. mimetic the half patient, of and specific in with results will patient the events an in
PTG-XXX, one, our With antagonist, will patient. And UC study oral the quarter receptor is in an with that file of study integrin Don? forward the year last pertain wherein and sharing overview in then out to PD over finishing turn Our we fourth filing a six IND to designed fourth milestone we X the Phase the Janssen antagonist, guide two the to XXXX. the the wherein milestones year-end to, of U.S. will half And study. end I the then of alpha-X-beta-X look first Don expect half to data and the oral Phase regard financial the by the IL-XX call in year of our now now, to year, first results. for Phase this last, X X which IND review PN-XXX,
